Limited Partner Analyst / Senior Analyst

Correction: Entera to participate in upcoming fall investor conferences. TEL AVIV, Israel, Aug. 27, 2026 (GLOBE NEWSWIRE) - Entera Bio Ltd. (NASDAQ: ENTX) ("Entera" or the "Company"), a leader in the development of oral peptides, today announced that the Company's Chief Executive Officer, Miranda Toledano, will be participating in the following upcoming fall investor conferences: 2026 Cantor Global Healthcare Conference Fireside Chat: September 10, 2026 at 1:00 p.m. Eastern Time, Waldorf Astoria New York, 301 Park Avenue, New York, NY Guggenheim Securities 3rd Annual Healthcare Innovation Conference November 9, 2026, Fireside Chat and 1x1 Meetings, Location: Boston, MA Evercore ISI 9th Annual Healthcare Conference November 30-December 2, 2026, in person, Location: Miami, FL About Entera Entera is a clinical stage company focused on developing oral peptide and protein replacement therapies for significant unmet medical needs where an oral tablet form holds the potential to transform the standard of care. The Company leverages a disruptive and proprietary technology platform (N-Tab(R) and its pipeline of first-in-class oral peptide programs. The Company's most advanced product candidate, EB613 (oral PTH(1-34)), is being developed as the first oral, osteoanabolic (bone building) once-daily tablet for osteoporosis. A placebo-controlled, dose-ranging Phase 2 study of EB613 tablets (n = 161) met primary (PD/bone turnover biomarker) and secondary endpoints (BMD). Entera is also developing the first oral Long Acting PTH(1-34) tablet as a replacement therapy for patients with hypoparathyroidism (EB612), the first oral oxyntomodulin, a dual targeted GLP1/glucagon peptide tablet for the treatment of obesity and metabolic syndromes; and the first oral GLP-2 tablet as an injection-free alternative for patients suffering from rare malabsorption conditions such as short bowel syndrome in collaboration with OPKO Health, Inc. For more information on Entera, visit www.enterabio.com or follow us on LinkedIn, Twitter, and Facebook. Cautionary Statement Regarding Forward Looking Statements Various statements in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements (other than statements of historical facts) in this press release regarding our prospects, plans, financial position, business strategy, clinical development activities, collaboration arrangements and expected financial and operational results are forward-looking statements. Words such as, but not limited to, "anticipate," "believe," "can," "could," "expect," "estimate," "design," "goal," "intend," "may," "might," "objective," "plan," "predict," "project," "target," "likely," "should," "will," and "would," or the negative of these terms and similar expressions or words, identify forward-looking statements. Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Forward-looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved. Important factors that could cause actual results to differ materially from those reflected in Entera's forward-looking statements include, among others: changes in the interpretation of clinical data; results of our clinical trials; the FDA's interpretation and review of our results from and analysis of our clinical trials; unexpected changes in our ongoing and planned preclinical development and clinical trials, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates; the potential disruption and delay of manufacturing supply chains; loss of available workforce resources, either by Entera or its collaboration and laboratory partners; impacts to research and development or clinical activities that Entera may be contractually obligated to provide; overall regulatory timelines; the size and growth of the potential markets for our product candidates; the scope, progress and costs of developing Entera's product candidates; Entera's reliance on third parties to conduct its clinical trials; Entera's ability to establish and maintain development and commercialization collaborations; Entera's operation as a development stage company with limited operating history; Entera's competitive position with respect to other products on the market or in development for the treatment of osteoporosis, hypoparathyroidism, short bowel syndrome, obesity, metabolic conditions and other disease categories it pursues; Entera's ability to continue as a going concern absent access to sources of liquidity; Entera's ability to obtain and maintain regulatory approval for any of its product candidates; Entera's ability to comply with Nasdaq's minimum listing standards and other matters related to compliance with the requirements of being a public company in the United States; Entera's intellectual property position and its ability to protect its intellectual property; and other factors that are described in the "Cautionary Statement Regarding Forward-Looking Statements," "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Entera's most recent Annual Report on Form 10-K filed with the SEC, as well as Entera's subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. There can be no assurance that the actual results or developments anticipated by Entera will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Entera. Therefore, no assurance can be given that the outcomes stated or implied in such forward-looking statements and estimates will be achieved. Entera cautions investors not to rely on the forward-looking statements Entera makes in this press release. The information in this press release is provided only as of the date of this press release, and Entera undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent required by law. Company Contact: [email protected]

Evercore hires pair of baird defense bankers in Washington. August 25, 2026 at 8:34 AM PDT Takeaways by bloomberg aisubscribe. Evercore Inc. has hired senior bankers Jean Stack and John Song from Robert W. Baird & Co. to bulk up its aerospace and defense as well as government services work, according to people familiar with the matter. Stack and Song will start in a few months in the Washington area, where Evercore will likely be expanding its presence with a new office in Virginia, the people said, asking not to be identified because the matter is private. Both will be senior managing directors, the people added.

Buyout firm Vista explores $3 billion sale of private markets data provider Allvue, sources say. Amy-Jo Crowley, David French and Milana Vinn By Amy-Jo Crowley, David French and Milana Vinn LONDON/NEW YORK, Aug 21 (Reuters) - Vista Equity Partners is weighing a potential sale of Allvue Systems, in a deal that could value the provider of data and analytics for asset managers and credit investors at as much as $3 billion including debt, four people familiar with the matter said. The move comes almost five years since Allvue's efforts to list via an initial public offering on the New York Stock Exchange were thwarted by the end of a bull run in financial technology stocks in the fall of 2021. While many companies have struggled with subdued investor interest and depressed valuations in the years since, 2026 has seen a recovery in deal-making efforts involving specialized financial technology and data providers which have businesses resilient to the growth of artificial intelligence. Against this more positive backdrop, Vista has engaged bankers at Evercore and Barclays to explore sale options for the Miami-headquartered Allvue, whose products help manage investments, track performance and streamline back-office operations. Discussions with potential buyers are at an early stage, said the sources who cautioned that no deal was guaranteed and spoke on condition of anonymity to discuss confidential information. Vista and Barclays declined comment. Allvue and Evercore did not respond to comment requests. Vista formed Allvue Systems in 2019 by acquiring AltaReturn and merging it with its existing portfolio company, Black Mountain Systems. The company has since expanded through acquisitions, including private markets software firm PFA Solutions in 2024. Allvue now generates more than $200 million in annual recurring revenue, one of the people said. Allvue could fetch somewhere between $2 billion and $3 billion in the event of a sale, said the person and a further source, based on the firm's annual growth rate of more than 15%, margins exceeding 30%, and valuations achieved by comparable companies in the sectors. By comparison, when Vista pulled Allvue's IPO in September 2021, it was seeking a valuation of around $1.7 billion. As well as broader sector tailwinds, Allvue should benefit from perceived scarcity value, given few of its peers are not already inside large financial institutions. For example, BlackRock completed its £2.55 billion ($3.5 billion) acquisition of Preqin in March 2025. (Reporting by Amy-Jo Crowley in London and David French and Milana Vinn in New York; Editing by Alistair Bell)